San Diego, California — May 6, 2026 — Leads & Copy — Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced its financial results for the first quarter ended March 31, 2026.
Total revenues for the quarter were $268 million, a 10% increase compared to the first quarter of 2025, when revenues were $244 million. Revenues were up 11% compared to non-GAAP adjusted total revenues of $242 million in the first quarter of 2025.
According to Chief Executive Officer Catherine Owen Adams, DAYBUE generated sales of $101 million. She noted the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and the initial uptake during the focused launch. NUPLAZID generated $167 million in sales, supported by strong new referrals and underlying demand, with performance strengthening as the quarter progressed.
Acadia is reaffirming its full year guidance and remains focused on advancing its pipeline, with remlifanserin representing a key value driver as the company approaches expected Phase 2 topline data in Alzheimer’s disease psychosis later this year.
Other company updates include:
The full launch of DAYBUE STIX (trofinetide) in the U.S. is underway, with approximately 30% of STIX patients being either treatment-naive or returning after previously discontinuing the liquid formulation.
Phase 2 topline results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026.
Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe.
A Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome.
GAAP net product sales of NUPLAZID were $167 million for the first quarter of 2026, up 5% compared to GAAP net product sales of $160 million for the first quarter of 2025, and up 6% as compared to non-GAAP adjusted net product sales of $157 million for the first quarter of 2025.
Net product sales of DAYBUE were $101 million for the first quarter of 2026, an increase of 20% as compared to $85 million for the first quarter of 2025.
Research and development expenses for the first quarter of 2026 were $77 million, compared to $78 million for the same period of 2025.
Selling, general and administrative expenses for the first quarter of 2026 were $171 million, compared to $126 million for the same period of 2025. The increase was primarily driven by increased investments to support continued growth of NUPLAZID and DAYBUE.
For the first quarter of 2026, Acadia reported net income of $4 million, or $0.02 per diluted share, compared to a net income of $19 million, or $0.11 per diluted share, for the same period in 2025.
At March 31, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $851 million, compared to $820 million at December 31, 2025.
Acadia is reaffirming its 2026 financial guidance, which was first provided on February 25, 2026:
Total revenues are expected to be in the range of $1.22 to $1.28 billion.
NUPLAZID net product sales are expected to be in the range of $760 to $790 million.
DAYBUE net product sales are expected to be in the range of $460 to $490 million.
R&D expense is expected to be in the range of $385 to $410 million.
SG&A expense is expected to be in the range of $660 to $700 million.
Acadia will host a conference call to discuss the first quarter 2026 results on Wednesday, May 6, 2026, at 1:30 p.m. PT/4:30 p.m. ET.
Acadia is committed to turning scientific promise into meaningful innovation for underserved neurological and rare disease communities. Its commercial portfolio includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. The company is developing therapeutic advancements with a pipeline that includes programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs.
1Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51.
Source: Acadia Pharmaceuticals
